Geocann and Sunderstorm expand KANHA brand internationally, becoming the first North American cannabis edibles brand to launch in Asia
08 déc. 2022 12h45 HE
|
Geocann
FORT COLLINS, Colo., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Geocann and Sunderstorm are proud to announce the expansion of their partnership to key international markets that will begin with Thailand....
Cingulate Benzinga All Live Access Appearance Rescheduled for December 16
01 déc. 2022 14h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate to Participate in Benzinga All Live Access Event
30 nov. 2022 15h00 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Oral Drug Delivery Global Market Report 2022: Rising R&D and Partnerships Between Key Players Driving Growth
11 nov. 2022 08h33 HE
|
Research and Markets
Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) -- The "Oral Drug Delivery Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.People are embracing a more...
Geocann expands cannabis scientific research leadership with first human β-caryophyllene (BCP) published study demonstrating the safety and performance of novel formulation
09 nov. 2022 15h15 HE
|
Geocann
FORT COLLINS, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Geocann is proud to announce that the peer-reviewed journal, Molecules, has published the results of a randomized, double-blind, cross-over...
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead Candidate for Treatment of ADHD
01 nov. 2022 09h02 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update
24 oct. 2022 16h45 HE
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Rapid progression in Drug Delivery techniques will bolster the Oral Controlled Release Drug Delivery Technology Market to reach US$ 68.4 Bn by 2032 end. Data by Future Market Insights, Inc.
17 oct. 2022 06h30 HE
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The global oral controlled release drug delivery technology market is expected to reach a value of US$ 68.4 Bn in 2032, with sales growing at a healthy...
Pharmaceutical Drug Delivery Global Market Report 2022: Featuring 3M, AstraZeneca, Pfizer, Bayer, Novartis, Merck & More
29 sept. 2022 04h28 HE
|
Research and Markets
Dublin, Sept. 29, 2022 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drug Delivery Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global pharmaceutical drug...
Cingulate Presents Data for Its Triple-Release Buspirone Product Candidate: CTx-2103
19 sept. 2022 06h45 HE
|
Cingulate Inc.
Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release™ (PTR™)...